rs505802 — SLC22A12

SLC22A12 rs505802 — The URAT1 Promoter Variant That Sets Your Urate Reabsorption Baseline

Every day your kidneys filter about 50 mg/dL of uric acid from the blood, but roughly 90% of that filtered urate gets reabsorbed — pulled back into the bloodstream before it can reach your urine. The single most important protein doing that reabsorption is URAT1¹¹ URAT1
Urate Transporter 1, encoded by SLC22A12 — the primary apical urate/anion exchanger in the renal proximal tubule. The rs505802 variant sits in the promoter region of SLC22A12 and influences how much URAT1 transporter your kidneys produce, directly setting the dial on how aggressively your body reclaims uric acid from the urine.

This makes rs505802 the third piece of a gout genetic panel alongside SLC2A9 (GLUT9, the basolateral urate transporter) and ABCG2 (the intestinal and renal secretory transporter). While SLC2A9 and ABCG2 variants alter the transporter protein itself, the SLC22A12 rs505802 variant operates upstream — it modulates the quantity of transporter produced rather than its per-molecule efficiency.

The Mechanism

rs505802 is located 2 kb upstream of SLC22A12 in the gene's regulatory region. The SLC22A12 promoter contains binding sites for HNF1α/β²² HNF1α/β
Hepatocyte nuclear factor 1 alpha and beta, transcription factors that drive kidney-specific URAT1 expression and estrogen response elements, both of which regulate tissue-specific expression. The C allele is associated with higher URAT1 expression and consequently greater renal urate reabsorption, while the T allele is associated with lower expression and more permissive urate excretion into the urine.

The variant is in near-perfect linkage disequilibrium (r² = 1 in Caucasians) with rs11231825 and rs11602903 in the SLC22A12 promoter region, meaning all three SNPs effectively tag the same functional haplotype. In African-ancestry populations, LD between these variants is lower, which is consistent with greater haplotype diversity.

URAT1 functions as an anion exchanger in the apical (luminal) membrane of proximal tubule cells: it swaps intracellular organic anions (lactate, nicotinate, pyrazinoate) for luminal urate, driving urate reabsorption. This is why URAT1 is the primary pharmacological target for uricosuric drugs — probenecid, lesinurad, benzbromarone, verinurad, and dotinurad all work by blocking this exchange, forcing more urate into the urine.

The Evidence

GWAS discovery and replication: The SLC22A12 locus was identified as genome-wide significant for serum uric acid in a meta-analysis of 28,141 Europeans (P = 2 × 10⁻⁹) Kolz et al., Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genetics, 2009³³ Kolz et al., Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genetics, 2009. Subsequent GWAS in Japanese (121,745 subjects, P = 1 × 10⁻³⁰⁰) and cross-ancestry cohorts (1,029,323 individuals, P = 5 × 10⁻³⁶⁰) confirmed rs505802 as one of the most robustly associated loci for serum urate in the human genome Cho et al., Large-scale cross-ancestry genome-wide meta-analysis of serum urate. Nature Communications, 2024⁴⁴ Cho et al., Large-scale cross-ancestry genome-wide meta-analysis of serum urate. Nature Communications, 2024.

Gout association: In 622 Han Chinese male gout cases and 917 controls, the T allele of rs505802 was protective against gout with an odds ratio of 0.747 (corrected P = 0.007), equivalent to a 25% reduction in gout risk per T allele Li et al., BMC Medical Genetics, 2015⁵⁵ Li et al., BMC Medical Genetics, 2015. A large PheWAS analysis confirmed the association: the T allele reduced gout risk with OR 0.86 (P = 1 × 10⁻⁹⁵) and was also associated with reduced gout medication use (P = 3 × 10⁻¹⁵) Verma et al., 2024⁶⁶ Verma et al., 2024.

Metabolic syndrome connection: In a study of 414 hypertensive patients, SLC22A12 promoter SNPs (including rs505802) explained 7% of BMI variation in Caucasians and were associated with metabolic syndrome (P = 0.033) Eraly et al., Kidney and Blood Pressure Research, 2012⁷⁷ Eraly et al., Kidney and Blood Pressure Research, 2012. This connects urate transport genetics to broader metabolic health beyond gout alone.

Effect size: The per-allele effect of rs505802 on serum urate is approximately −0.06 to −0.10 mg/dL per T allele across populations, with the largest effects observed in East Asian cohorts where the C allele is most prevalent. While smaller per-allele than SLC2A9, the population-level impact is substantial because of the high C allele frequency in non-European populations.

Practical Actions

The rs505802 genotype informs urate management through two key mechanisms: baseline risk stratification and pharmacological context. CC carriers have genetically elevated URAT1 expression, meaning their kidneys are programmed to reabsorb more uric acid. This creates a higher baseline that dietary purines, alcohol, and fructose push further upward.

For pharmacological context, CC carriers may respond more strongly to uricosuric drugs (probenecid, lesinurad, benzbromarone) because they have more URAT1 transporter to inhibit — this is the very target these drugs block. Conversely, TT carriers who already have lower URAT1 expression may derive less incremental benefit from uricosurics and might respond better to xanthine oxidase inhibitors (allopurinol, febuxostat) that reduce urate production instead.

Interactions

SLC2A9 (rs3733591) and ABCG2 (rs2231142): The three major urate transport genes — SLC22A12 (apical reabsorption via URAT1), SLC2A9 (basolateral reabsorption via GLUT9), and ABCG2 (apical secretion via BCRP) — operate at independent points in the renal urate handling pathway. Risk alleles at multiple loci compound additively. An individual carrying rs505802 CC, SLC2A9 rs3733591 CC, and ABCG2 rs2231142 TT has maximal urate reabsorption, minimal urate secretion, and substantially elevated gout risk beyond any single variant alone.

Estrogen and sex-specific effects: The SLC22A12 promoter contains estrogen response elements, and URAT1 expression is modulated by estrogen status. Pre-menopausal women have lower urate levels in part because estrogen suppresses URAT1 expression; post-menopausal women lose this protection. The rs505802 C allele effect may be amplified after menopause as estrogen-mediated transcriptional suppression of SLC22A12 is lost.

Uricosuric drug response: Probenecid, lesinurad, and benzbromarone all inhibit URAT1 directly. Individuals with higher URAT1 expression (CC genotype) have a larger pharmacological target for these drugs and may show a more robust uricosuric response. This pharmacogenomic relationship has not yet been confirmed in prospective clinical trials but is mechanistically well-supported.